Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study
The entirety of the $155,964 grant supplement will be provided to UCLA as a subcontractor to conduct the study.
- The entirety of the $155,964 grant supplement will be provided to UCLA as a subcontractor to conduct the study.
- The grant supplement is related to the $6.4 million NIH grant for the Early Feasibility Clinical Trial of a Visual Cortical Prosthesis, grant UH3NS103442.
- Second Sight reported promising two-year data from the Orion trial on May 12, 2021.
- About Second Sight Medical Products, Inc.
Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.